



# **Gemcitabine (Hydrochloride)**

Catalog No: tcsc0755



## **Available Sizes**

Size: 500mg

Size: 1g



# **Specifications**

CAS No:

122111-03-9

#### Formula:

 $C_9H_{12}CIF_2N_3O_4$ 

#### **Pathway:**

Cell Cycle/DNA Damage; Cell Cycle/DNA Damage; Autophagy

#### **Target:**

Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; Autophagy

#### **Purity / Grade:**

>98%

## **Solubility:**

 $H2O : \ge 66.66 \text{ mg/mL} (222.45 \text{ mM})$ 

#### **Alternative Names:**

LY 188011 hydrochloride

## **Observed Molecular Weight:**

299.66

# **Product Description**

Gemcitabine hydrochloride is a **DNA synthesis** inhibitor with **IC**<sub>50</sub> of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively.





IC50 & Target: DNA synthesis<sup>[1]</sup>

In Vitro: MTS assay demonstrates that Gemcitabine at 15 nM, indole-3-carbinol (I3C) at 50  $\mu$ M and the combination does not affect hTERT-HPNE cell viability. However, treatment with Gemcitabine at 15 nM, I3C at 50  $\mu$ M and the combination results in 31%, 19% and 72% cell death of BxPC-3 cells, respectively<sup>[1]</sup>.

*In Vivo:* The aim of study is to formulate PLGA nanoparticles (NPs) of Gemcitabine Hydrochloride (Gemcitabine HCl) for enhanced oral bioavailability via absorption through M cells of Peyer's patches. Gemcitabine HCl is available as i.v. infusion due to its short half life (8-17 min), rapid metabolism and limited tumor uptake. Gemcitabine loaded PLGA NPs shows 21.47-fold increase in relative bioavailability in comparison to plain drug solution after oral delivery<sup>[2]</sup>. After i.v. injection of Gemcitabine at doses of 50, 100, and 120, and 300 mg/kg, the highest dose caused considerable body weight loss (p10) and 100 mg/kg is considered as the maximal tolerated dose, which does not cause any mortality and a minimal body weight loss<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!